Diabetes mellitus (DM) increases the risk of viral infections especially during the period of poor glycemic controls. Emerging evidence has reported that DM is one of the most common comorbidities in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection, also referred to as COVID-19. Moreover, the management and therapy are complex for individuals with diabetes who are acutely unwell with suspected or confirmed COVID-19. Here, we review the role of antidiabetic agents, mainly including insulin, metformin, pioglitazone, dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists in DM patients with coronavirus infection, addressing the clinical therapeutic choices for these subjects.
【저자키워드】 COVID-19, Coronavirus infection, Diabetes Mellitus, antidiabetic agents, therapeutic choices, 【초록키워드】 viral infection, coronavirus, SARS-CoV2, therapy, Infection, peptide, Comorbidity, risk, inhibitors, DPP4, Dipeptidyl peptidase-4, management, therapeutic, Patient, receptor, insulin, Evidence, acute respiratory syndrome, individual, complex, agonist, controls, reported, increase, subjects, diabete, glycemic, 【제목키워드】 drug, antidiabetic,